You are on page 1of 4



1. Zaidi AA, Vesole DH. Multiple myeloma: an old disease with new hope
for the future. CA Cancer J Clin. 2001;51:273-85.
2. Sonneveld P, Schmidt-Wolf IGH, Holt BVD, Jarari LE, Bertsch U,
Salwender H, et al. Bortezomib induction and maintenance treatment in
patients with newly diagnosed multiple myeloma: results of the
randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol
3. Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jiminez J,Rubla JDL,
et al. Superiority of bortezomib, thalidomid, and dexamethasone (VTD) as
induction pretransplantation therapy in multiple myeloma: a randomized
phase 3 PETHEMA/GEM study. Blood 2012;120(8):1589-96.
4. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al.
Bortezomib with thalidomid plus dexamethasone compared with
thalidomide plus dexamethasone as induction therapy before, and
consolidation therapy after, double autologous stem-cell transplantation in
newly-diagnosed multiple myeloma: arandomised phase 3 study. Lancet
5. Palumbo A, Bringhen S, Rossi D,Cavalli M, Larocca A, Ria R, et. al.
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance
with bortezomib-thalidomide compared with bortezomib-melphalan-
prednisone for initial treatment of multiple myeloma: a randomized
controlled trial. J Clin Oncol 2010;28:5101-9.
6. Mateos M-V, Oriol A, Lopez JM, Teruel AI, Guia ALDL, Lopez J, et al.
GEM 2005 trial update comparing VMP/VTP as induction in elderly
multiple myeloma patients: do we still need alkylators? Blood
7. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, et al.
Efficacy of melphalan and prednisone plus thalidomide in patients older
than 75 years with newly diagnosed multiple myeloma : IFM 01/01 trial. J
Clin Oncol. 2009;22:3664-70.
8. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, et al.
Thalidomide for previously untreated elderly patients with multiple

Lee JH. Anaissie E. 2004.2(5):76-81. 2013. 18. Kim K. Larocca A. 2011. 8th ed. Hajek R. Indonesian J Cancer.32:1-17. Kipps TJ. Seligsohn U. In: Kaushansky K. Yoon SS. treatment. Kosasih AA. Angtuaco E. New approaches to management of multiple myeloma. Rajkumar SV. and outcome in multiple myeloma patients in different geographical areas of the world.1(28):3-11. Blood 2011. Patel P. Epidemiology. Kyle RA. editors. 14. 17. Drug therapy multiple myeloma. San Miguel JF. Shimizu K. 11. Blood 2009. 12. J Adv Intern Med 2012. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Genadieva-Stavric S. Palumbo A. Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. Multiple myeloma in Indonesia. Saraf S. Beuler E. Rhee FV. Sumantri R.11(23):6063-73. Prchal JT. Multiple myeloma : An update. 39 myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.113:3435–3442. et al. Kim JS. Palumbo A. Supandiman I. et al. Morgan G. Reksodiputro AH. Tóthová E et al. and supportive care for myeloma patients who are not eligible for standard autologous stem-cell transplantation. Niezvizky R.1645-81. 9. Cavallo F. 13. Lichtman MA. Curr Treat Opt Oncol 2014. Cavo M.351:1860-73. Rondelli D. . 2014.118:1239-47. Palumbo A. New York: Mc Graw Hill.89:751-6. Orlowski R. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem-cell transplantation. Blade J. Williams Hematology. Am J Hematol. Al-Farsi K. Myeloma. et al. Min CK. Nair B. Ludwig H. International Myeloma Working Group consensus statement for the management. 15. Rajkumar SV. Toruan T. 2011. J Clin Oncol.01:20-32. biology. Bartel T. Oman Med J. Rajkumar SV. 2010. Moraeu P. Tadjoedin H. et al. 10. 16. et al. Blood.15(2):157- 70.p. Epstein J. 2014. N Engl J Med.

Miguel JS. 27. Anderson K. Ozasa K. Management of multiple myeloma in Asia: resource-startified guidelines.120 Suppl 12:40-61. Mori Mitsuru. Risk factor for multiple myeloma: Evidence from the Japan Collaborative Cohort (JACC) Study. 2006. N Engl J Med 2011. Cole P. Anderson K. Buadi FK. Leukemia. Chanan-Khan AA. International uniform response criteria for multiple myeloma. Khan MM. Attal M. et al. Chim CS. Barlogie B. Improved survival in multiple myeloma and the impact of novel therapies.15(28):2612-24. Nawarawong SY. Schaafsma R. Hwang SY. Mink PJ. 2010. Adami HO. Blade J. et al. 28. 23.5(111):2516-20. Frontline therapy of multiple myeloma. Tan D. Multiple Myeloma. . 24. Mateos MV. Blood. Stewart AK.98:980-7. Acta Biochim Biophys Sin. Larocca A. Oriol A. Larocca A. and the impact of novel agents. Giralt S. Mandel JS. 26.364:1046-60. Matsuo K. Gay F. Zhu Y. Chou T. et al. 2011.20:3076-84. Lancet 2013. 40 19. Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials. 2008. 25. Int J Cancer. Sakauchi Fumio. et al. Importance of achieving a complete response in multiple myeloma. Falcone AP.7:575-81 22. Durie BGM. J Clin Oncol. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Harousseau JL. Tamakoshi A. Dispenzieri A. 2015.117:3025-31. 20. Chang X. Blood. 30.14:571-9. 2014. Haematologica 2013.46(3):240-7. Moreau P. Wijermans P.20:1467-73. Palumbo A. 21. Blood. Oken MM. Alexander DD. Kumar SK. Asian Pac J Cancer Prev. Rajkumar SV. Hayman SR. Mechanism of immunomodulatory drugs’ action in the treatment of multiple myeloma. et al. 29. 2007. Rossi D. et al. Shi C. Facon T. Sinuraya ES. 2006. Zweegman S. Lacy MQ. Multiple myeloma: a review of the epidemiologic literature. 2006. Bringhen S. Registrasi Kanker Rumah Sakit Kanker Dharmais tahun 1993-2010. Chng WJ. Cavallo F.

41 .